GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » Operating Margin %

Dynavax Technologies (Dynavax Technologies) Operating Margin % : -15.27% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Dynavax Technologies's Operating Income for the three months ended in Dec. 2023 was $-8.5 Mil. Dynavax Technologies's Revenue for the three months ended in Dec. 2023 was $55.6 Mil. Therefore, Dynavax Technologies's Operating Margin % for the quarter that ended in Dec. 2023 was -15.27%.

The historical rank and industry rank for Dynavax Technologies's Operating Margin % or its related term are showing as below:

DVAX' s Operating Margin % Range Over the Past 10 Years
Min: -28508.26   Med: -586.32   Max: 39.09
Current: -11.07


DVAX's Operating Margin % is ranked worse than
73.14% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 6.385 vs DVAX: -11.07

Dynavax Technologies's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Dynavax Technologies's Operating Income for the three months ended in Dec. 2023 was $-8.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.7 Mil.


Dynavax Technologies Operating Margin % Historical Data

The historical data trend for Dynavax Technologies's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Operating Margin % Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -344.95 -161.59 30.38 39.09 -11.07

Dynavax Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.22 -38.22 -5.65 5.92 -15.27

Competitive Comparison of Dynavax Technologies's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Operating Margin % falls into.



Dynavax Technologies Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Dynavax Technologies's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-25.715 / 232.284
=-11.07 %

Dynavax Technologies's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-8.491 / 55.596
=-15.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dynavax Technologies  (NAS:DVAX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Dynavax Technologies Operating Margin % Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (Dynavax Technologies) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Executives
Robert Janssen officer: Chief Medical Officer and VP C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack officer: Senior Vice President 39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess officer: Principal Accounting Officer C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer officer: Co-President and Senior VP C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald officer: SVP and CFO 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman officer: Chief Science Officer and VP C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach officer: VP, CBO, and General Counsel 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063